国家药监局：全过程深化药品监管改革 全方位筑牢药品安全底线

Core Viewpoint - The 36th Pharmaceutical Economic Information Conference emphasized the need for comprehensive implementation of regulatory reforms in the pharmaceutical industry to enhance drug safety and promote high-quality development [1] Group 1: Regulatory Reforms - The National Medical Products Administration (NMPA) aims to fully implement the spirit of the 20th National Congress of the Communist Party of China [1] - The NMPA is committed to deepening drug regulation reforms throughout the entire process and supporting high-quality development across the industry [1] Group 2: Public Health Contribution - The reforms are designed to strengthen the safety baseline of pharmaceuticals and contribute significantly to the protection and promotion of public health [1]